Literature DB >> 19762731

Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options.

Joan Benca1, Kirk Hogan.   

Abstract

Clinical episodes and abnormal laboratory tests compatible with a diagnosis of malignant hyperthermia have been observed in patients with a diversity of syndromes, enzymopathies, and coexisting disorders thereby raising the likelihood of causal associations and heightened perioperative risk in others carrying a shared diagnosis. In the present review, we survey available published series, case reports, and the results of contracture testing in patients identified by others to be potentially predisposed to malignant hyperthermia. For most conditions, evidence for a causal relationship with malignant hyperthermia susceptibility is weak. The review concludes with suggestions for clinical management when evidence for or against an association is uncertain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762731     DOI: 10.1213/ane.0b013e3181adca28

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  13 in total

1.  [Anesthesia with neuromuscular diseases].

Authors:  M U Gerbershagen; F Wappler
Journal:  Anaesthesist       Date:  2010-10       Impact factor: 1.041

Review 2.  A comprehensive review of malignant hyperthermia: Preventing further fatalities in orthopedic surgery.

Authors:  Jennifer L Smith; Meaghan A Tranovich; Nabil A Ebraheim
Journal:  J Orthop       Date:  2018-05-07

Review 3.  [Malignant hyperthermia].

Authors:  T Metterlein; F Schuster; B M Graf; M Anetseder
Journal:  Anaesthesist       Date:  2014-12       Impact factor: 1.041

Review 4.  Special article: Future directions in malignant hyperthermia research and patient care.

Authors:  Sharon J Hirshey Dirksen; Marilyn Green Larach; Henry Rosenberg; Barbara W Brandom; Jerome Parness; Robert Scott Lang; Meera Gangadharan; Tyler Pezalski
Journal:  Anesth Analg       Date:  2011-06-27       Impact factor: 5.108

5.  A family with discordance between malignant hyperthermia susceptibility and rippling muscle disease.

Authors:  Jimmy Sundblom; Atle Melberg; Franz Rücker; Anja Smits; Gunilla Islander
Journal:  J Anesth       Date:  2012-09-14       Impact factor: 2.078

6.  Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.

Authors:  Georgirene D Vladutiu; Paul J Isackson; Kenneth Kaufman; John B Harley; Beth Cobb; Lisa Christopher-Stine; Robert L Wortmann
Journal:  Mol Genet Metab       Date:  2011-07-12       Impact factor: 4.797

Review 7.  Inborn errors of energy metabolism associated with myopathies.

Authors:  Anibh M Das; Ulrike Steuerwald; Sabine Illsinger
Journal:  J Biomed Biotechnol       Date:  2010-05-26

8.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

9.  Malignant hyperthermia.

Authors:  Dong-Chan Kim
Journal:  Korean J Anesthesiol       Date:  2012-11-16

10.  Mechanisms underlying neonate-specific metabolic effects of volatile anesthetics.

Authors:  Julia Stokes; Arielle Freed; Rebecca Bornstein; Kevin N Su; John Snell; Amanda Pan; Grace X Sun; Kyung Yeon Park; Sangwook Jung; Hailey Worstman; Brittany M Johnson; Philip G Morgan; Margaret M Sedensky; Simon C Johnson
Journal:  Elife       Date:  2021-07-13       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.